Gsk (GSK) Enterprise Value (2026)

Gsk (GSK) has 18 years of Enterprise Value data on file, last reported at $107.7 billion in Q3 2026.

• For the quarter ending Q3 2026, Enterprise Value changed N/A year-over-year to $107.7 billion; the trailing twelve-month figure through Sep 2026 stood at $107.7 billion (changed N/A YoY), and the FY2025 full-year result was $100.6 billion, up 48.99% from the prior year.
• Enterprise Value was $107.7 billion for Q3 2026 at Gsk, roughly flat from $108.2 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $114.1 billion in Q1 2026 to a low of $59.0 billion in Q3 2022.
• A 5-year average of $84.7 billion and a median of $78.6 billion in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value slumped 31.35% in 2022 and surged 49.04% in 2025, its largest moves.
• Gsk's Enterprise Value stood at $70.6 billion in 2022, then grew by 6.86% to $75.4 billion in 2023, then declined by 10.52% to $67.5 billion in 2024, then surged by 49.04% to $100.6 billion in 2025, then increased by 7.05% to $107.7 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $107.7 billion in Q3 2026, $108.2 billion in Q2 2026, and $114.1 billion in Q1 2026.